Safety and efficacy of melatonin as an adjuvant therapy in COVID-19 patients: Systematic review and meta-analysis.

Safety and efficacy of melatonin as an adjuvant therapy in COVID-19 patients: Systematic review and meta-analysis.

Publication date: Sep 22, 2023

Melatonin might be beneficial to coronavirus disease 2019 (COVID-19) patients in terms of both prevention and treatment. We investigated how melatonin affected various clinical and laboratory results in COVID-19 patients. PubMed, Scopus, Cochrane Library and Web of Science databases were utilized for searching eligible articles fulfilling our inclusion criteria up to December 2022. We used random effect model in case of significant heterogeneity; in other cases, a fixed model was applied. RevMan was used for meta-analysis. We included 11 studies in our review. Clinical improvement rate was found to be statistically significantly higher in patients taking melatonin than in the control group (OR: 5. 09; 95% CI: 2. 60-9. 96, p ‚Äč

Concepts Keywords
Coronavirus Adjuvant
December COVID-19
Library Efficacy
Systematic Melatonin
Therapy

Semantics

Type Source Name
drug DRUGBANK Melatonin
disease MESH COVID-19

Original Article

(Visited 1 times, 1 visits today)